Live feed09:45:00·48dPRReleasevia QuantisnowMAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion TrialByQuantisnow·Wall Street's wire, on your screen.MAIA· MAIA Biotechnology Inc.Health Care
